世界の下垂体性小人症治療市場 – 2030 年までの業界動向と予測

 下垂体性小人症治療市場の分析と規模

下垂体性小人症は、世界各地で、通常 1:30,000 から 1:1800 の範囲で発生します。成長ホルモンの欠乏につながる下垂体機能不全の症例が増加しているため、市場需要は急速に増加しています。成人の場合、成長ホルモンの欠乏は、エネルギーの低下、気分の落ち込み、極度の疲労、筋力の低下、筋肉量の低下、皮膚の薄さと乾燥、脂肪組織の増加、骨密度の低下につながる可能性があります。

データブリッジ市場調査は、2023年から2030年の予測期間における下垂体性小人症治療市場の成長率を分析しています。下垂体性小人症治療市場の予想CAGRは、上記の予測期間中に約14.50％になる傾向があります。市場は2022年に49億米ドルと評価され、2030年までに144.8億米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

下垂体性小人症治療市場の範囲とセグメンテーション

Market Definition

Pituitary dwarf is also known as growth hormone deficiency disorder. It is the type of condition wherein pituitary gland does not produce enough growth hormone, resulting in a child's slow growth pattern. Various symptoms include chubby body build, immature appearance, prominent forehead, below-average growth, and underdeveloped bridge of the nose among others. This condition starts emerging in childhood itself and becomes even more prominent when the child reaches puberty. The growth and development of the child slows down or gets delayed.

Pituitary Dwarf Treatment Market Dynamics

Drivers

• Increasing Demands of Diagnostic Tests

There are various diagnostic tests that are boosting the demand of the market. Several imaging tests such as X-rays are used as certain abnormalities of the skull and skeleton can specify the disorder the patient has. Numerous imaging devices may also show delayed maturation of bones, as is the case in growth hormone deficiency. A magnetic resonance imaging (MRI) scan may show abnormalities of the pituitary gland or hypothalamus, both of which play a major role in hormone function.  

Opportunities

•  Growing Demand of Different Treatment Methods

There are numerous treatment methods that are aiding in boosting the growth of the market. Subcutaneous injections are being provided on a daily basis as the dose of hormone therapy until the child finally reached an appropriate height. In girls, hormones such as estrogen and progesterone are added, on the other hand in boys, testosterone is added. Testosterone must be added very carefully as it can have a huge effect on children. Other drugs can also be used to surge the production of growth hormones. Drugs such as arginine, chlonidine, propranolol, and dopamine can be used efficiently. Other anabolic substances such as nandrolone, oxandrolone and fluoxinesterone, help in the stimulation of protein synthesis. This also increases cartilage and bone growth.

 Restraints/Challenges

• Side Effects of Pituitary Dwarf Treatment

The pituitary dwarf treatment is involved with several side effects such as rash and pain at the sight of the injection, transient fever, edema, increased insulin resistance and other such problems. This hampers the market growth.

• Discontinuation of Drug Trials

The drug development for the disease has faced major obstacles as numerous therapies have failed to demonstrate efficacy or were associated with major toxicity. Thus, this hampers the growth of the market.

This pituitary dwarf treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pituitary dwarf treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2021, Biocorp and Merck joined hands in the development and global distribution of a specific version of the Mallya device for applications in the field of HGH.
• In 2020, US FDA approved Novo Nordisk, Inc.’s Sogroya (somapacitan), as the first human growth hormone (HGH) therapy that adult patients only take once a week by injection under the skin

Global Pituitary Dwarf Treatment Market Scope

The pituitary dwarf treatment market is segmented on the basis of treatment, types, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Pituitary Dwarfism Type I
• Pituitary Dwarfism Type II
• Pituitary Dwarfism Type III
• Pituitary Dwarfism Type IV
• Others

Treatment

• Surgery
• Additional Therapy
• Drugs
• Others

Route of Administration

• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Pituitary Dwarf Treatment Market Regional Analysis/Insights

The pituitary dwarf treatment market is analyzed and market size insights and trends are provided by treatment, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the pituitary dwarf treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific will be expecting positive growth for pituitary dwarf treatment market throughout the forecasted period due to the continuously increasing population resulting increasing prevalence of dwarfism and other growth hormone deficiency disorders.

政府の啓発プログラムの強化、高度な技術と治療により、北米が市場を支配しています。 

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界の下垂体性小人症治療市場シェア分析

下垂体性小人症治療市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、下垂体性小人症治療市場に関連する会社の焦点にのみ関連しています。

下垂体性小人症治療市場で活動している主要企業は次のとおりです。

• テバ製薬工業株式会社（イスラエル）
• アムニール・ファーマシューティカルズLLC（米国）
• エレクタAB（スウェーデン）
• アルニラム・ファーマシューティカルズ（米国）
• アポテックス株式会社（カナダ）
• アルマタ・ファーマシューティカルズ社（米国）
• ファイザー社（米国）
• H. ルンドベック A/S (デンマーク)
• リリー（米国）
• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）

SKU-59143